Cargando…

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature

Background: Imatinib is the gold standard in the treatment of chronic myeloid leukemia (CML) patients. Resistance to imatinib is interfering with patients’ responses and their survivals. Materials and Methods: We designed a systematic search to find relevant studies by applying appropriate keywords...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amouei, Asiyeh, Daeian, Nesa, Khezrnia, Seyedeh Sana, Mansouri, Ava, Hadjibabaie, Molouk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381106/ https://www.ncbi.nlm.nih.gov/pubmed/34466210 http://dx.doi.org/10.18502/ijhoscr.v15i2.6042

Ejemplares similares

Prescribing Pattern and Prescription-writing Quality of Antineoplastic Agents in the Capital City of a Middle-income Developing Country
por: Taghizadeh-Ghehi, Maryam, et al.
Publicado: (2018)

Selenium supplementation in patients undergoing hematopoietic stem cell transplantation: effects on pro-inflammatory cytokines levels
por: Daeian, Nesa, et al.
Publicado: (2014)

High Prevalence of Vitamin D Deficiency in Newly Diagnosed Acute Myeloid Leukemia Patients and Its Adverse Outcome
por: Seyedalipour, Fatere, et al.
Publicado: (2017)

Types and severity of medication errors in Iran; a review of the current literature
por: Mansouri, Ava, et al.
Publicado: (2013)

Is ‘Self-Medication’ a Useful Term to Retrieve Related Publications in the Literature? A Systematic Exploration of Related Terms
por: Mansouri, Ava, et al.
Publicado: (2015)

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia
por: Moshfeghi, Kamran, et al.
Publicado: (2013)

Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies
por: Taghvaye-masoumi, Hamidreza, et al.
Publicado: (2021)

Is Supplementation Efficacious in Maintaining Adequate Plasma Levels of Vitamin A and E for Thalassemic Patients Undergoing Hematopoietic Stem Cell Transplantation? A Cross-Sectional Study
por: Hajimahmoodi, Mannan, et al.
Publicado: (2014)

Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients
por: Masoumi, Hamidreza Taghvaye, et al.
Publicado: (2017)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

Predictive performance of Vancomycin population pharmacokinetic models in Iranian patients underwent hematopoietic stem cell transplantation
por: Taghizadeh-Ghehi, Maryam, et al.
Publicado: (2015)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

A Review of Medication Errors in Iran: Sources, Underreporting Reasons and Preventive Measures
por: Mansouri, Ava, et al.
Publicado: (2014)

Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients
por: Zhu, Yu, et al.
Publicado: (2014)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
por: Jain, Parveen, et al.
Publicado: (2013)

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience
por: Adattini, Josephine A., et al.
Publicado: (2022)

The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature
por: Mohammadpour, Fatemeh, et al.
Publicado: (2018)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
por: Ibrahim, Ali, et al.
Publicado: (2022)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China
por: Deng, Mengyue, et al.
Publicado: (2020)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients
por: Ebrahimpour, Sholeh, et al.
Publicado: (2017)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase
por: Chuah, Charles T., et al.
Publicado: (2014)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
por: Scerni, Ana Carolina Costa, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ofdem7vgficfgtvnqsgr3ofs63